Phenomix Corporation Patent applications |
Patent application number | Title | Published |
20100323988 | SOLID CITRATE AND TARTRATE SALTS OF DPP-IV INHIBITORS - This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolid acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions. | 12-23-2010 |
20100323953 | MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS - The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment. | 12-23-2010 |
20100247642 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR - A dosage form is provided for an anti-diabetic DPP-IV inhibitor of formula (I) as its tartarate salt, wherein the purity of the active pharmaceutical ingredient is maintained over a prolonged storage period under conditions similar to those likely encountered in home storage of the medication by a diabetic patient. A formulation free of calcium salts such as calcium phosphate, but including microcrystalline cellulose, copovidone, crospovidone, colloidal silicon dioxide, and magnesium stearate, when compacted into a tablet with the active pharmaceutical ingredient, was shown to be stable for at least six months at 40° C. and 75% relative humidity. Methods for preparation of the dosage form are also provided. | 09-30-2010 |
20100204484 | CRYSTALLINE SYNTHETIC INTERMEDIATE FOR PREPARATION OF A DPP-IV INHIBITOR AND METHOD OF PURIFICATION THEREOF - The invention provides a crystalline form of a synthetic intermediate useful in the preparation of a DPP-IV inhibitor, a method for preparing the crystalline form of the intermediate, and a method of using the crystalline form of the intermediate in the preparation of the inhibitor. | 08-12-2010 |
20100120716 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR - Macrocyclic inhibitors of Hepatitis C protease are provided, the inhibitors including a boronic acid or ester group, a macrocyclic ring of about 13 to 25 atoms including at least two amide linkages, a proline-analogous group, and a connecting segment joining moieties on either side of the proline-analogous group. Methods of making the HCV protease-inhibitory compounds, methods of using the compounds, formulations of the compounds, and pharmaceutical combinations including the compounds, are provided. | 05-13-2010 |
20100120661 | HETEROCYCLIC BORONIC ACID COMPOUNDS - Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH | 05-13-2010 |
20100087658 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS - Methods and intermediates for the synthesis of selective inhibitors of dipeptidyl peptidase IV (DPP-IV) are provided. Coupling of a carboxylate salt with a boro-proline derivative provides a protected form of a DPP-IV inhibitor, which may be deblocked to yield the medicinal compound. The carboxylate salt can be a crystalline form of a sodium salt or a dicyclohexylammonium salt. The inhibitor can be used in the treatment of diabetes. | 04-08-2010 |